Cytoreductive Surgery in Ovarian Carcinoma Patients with a Documented Previously Complete Surgical Response

Vaccarello, Luis; Rubin, Stephen C.; Vlamis, Vaia; Wong, George Y.; Jones, Walter B.; Lewis, John L.; Hoskins, William J.

doi:10.1006/gyno.1995.1099

Cited by 131 publications

(65 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The current study revealed that liver metastasis is another important prognostic determinant. Vaccarello et al (1995) examined the relationship between site of recurrence and survival, and reported that liver metastasis had a negative influence on survival. In most studies, patients with liver metastasis were excluded from subjects for SCS.…”

Section: Discussionmentioning

confidence: 99%

“…Although only preoperative or intraoperative variables before starting SCS should be analysed for selection of the candidate, these variables have been analysed together with SCS outcome in most previous studies. In addition, the follow-up periods of living patients were rather short (the median or average follow-up periods were between 1 and 4 years) (Jänicke et al, 1992;Vaccarello et al, 1995;Cormio et al, 1999;Zang et al, 2000Zang et al, , 2004Munkarah et al, 2001;Scarabelli et al, 2001) in most of the previous reports.…”

mentioning

confidence: 99%

“…Recently, several investigators have reported the significant value of secondary cytoreductive surgery (SCS) in a subset of patients with recurrent ovarian cancer (Jänicke et al, 1992;Eisenkop et al, 1995Eisenkop et al, , 2000Vaccarello et al, 1995;Cormio et al, 1999;Zang et al, 2000Zang et al, , 2004Munkarah et al, 2001;Scarabelli et al, 2001;Tay et al, 2002). The value of complete resection at the time of SCS for highly selected patients is in consensus in these recent reports.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection

et al. 2005

View full text Add to dashboard Cite

The value of secondary cytoreductive surgery (SCS) for recurrent ovarian cancer is still controversial. The aim of this study was to clarify candidates for SCS. Between January 1987 and September 2000, we performed SCS in 44 patients with recurrent ovarian cancer, according to our selection criteria, disease-free interval (DFI) 46 months, performance status o3, no apparent multiple diseases, age o75years and no progressive disease during preoperative chemotherapy, if undertaken. The variables were investigated by univariate and multivariate analyses. Of 44 patients, 26 (59.1%) achieved complete removal of all visible tumours at SCS. Secondary cytoreductive surgery outcome, complete or incomplete resection, was significantly related to overall survival (P ¼ 0.0019). As for variables determined before SCS, DFI 412 months, no liver metastasis, solitary tumour and tumour size o6 cm were independently associated with favourable overall survival after recurrence in the multivariate analysis. Patients with three or all four variables (n ¼ 31) had significantly better survival compared with the other patients (n ¼ 13) (47 vs 20 months in median survival, Po0.0001). In these patients, fairly good median survival (40 months) was obtained even in patients with incomplete resection. Secondary cytoreductive surgery had a large impact on survival of patients with recurrent ovarian cancer when they had three or all of the above-mentioned four factors at recurrence. These patients should be considered as ideal candidates for SCS.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In published series, the technical success rates of SCR vary widely, from 37-47% 8,10,12 to 83%, 14 although the latter rate lacks credibility. The SCR procedures include enterolysis, visualization of all peritoneal surface, examination and removal of multiple histologic specimens, and intraperitoneal or retroperitoneal tumor resection.…”

Section: Surgical Techniques Of Scr and Outcome Determinantsmentioning

confidence: 99%

“…Those authors stated that, in the absence of efficacious second-line medical therapy, the value of secondary tumor-reductive surgery for recurrent EOC was limited. 9 However, Janicke et al 10 and other investigators 11,12 reported that a survival benefit was provided by successful secondary debulking surgery. Recent observations also indicate that SCR is feasible, well tolerated, and associated with significant prolongation of survival in selected patients with recurrent EOC.…”

mentioning

confidence: 99%

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?

Zang

Tang

et al. 2004

Cancer

138

View full text Add to dashboard Cite

Background: Persistent infection following endoscopic sinus surgery (ESS) for chronic rhinosinusitis (CRS) is a frustrating entity for the patient and rhinologist alike. Mupirocin nasal washes have been proposed as an efficacious treatment in such patients. Two small studies have reported excellent short‐term posttreatment outcomes; however, the long‐term microbiological outcomes following treatment are not known; likewise, the rate of mupirocin‐resistance following treatment has not been explored. Methods: This was a retrospective chart review of 61 patients with Staphylococcus aureus (S. aureus)‐positive surgically‐recalcitrant CRS having undergone 0.05% mupirocin nasal rinse treatment, twice daily for 4 weeks. Specific outcomes reported included posttreatment culture results, time to first posttreatment S. aureus culture, and mupirocin‐sensitivity following treatment. Results: Of 57 patients meeting minimal posttreatment follow‐up criteria, 42 (73.7%) progressed to microbiological failure by subsequently cultured S. aureus. Mean time to first positive culture was 144 days. Of the 42 patients who progressed to microbiological relapse, full antibiotic sensitivity data was available for 41; of these, only 1 was found to subsequently harbor a mupirocin‐resistant strain of S. aureus, thus yielding a posttreatment resistance rate of 2.4%. Conclusion: Treatment with mupirocin nasal washes in S. aureus–positive, surgically recalcitrant CRS has a high microbiological failure rate, with 73.7% of patients subsequently re‐culturing S. aureus. Our current treatment regime of 0.05% nasal washes twice daily for 4 weeks is associated with a posttreatment resistance rate that is consistent with other studies of topical mupirocin use, suggesting that mupirocin washes are no more likely to induce resistance than nasal vestibule decolonization in the high‐risk medical or surgical patient. © 2011 ARS‐AAOA, LLC.

show abstract

Secondary surgical cytoreduction for advanced epithelial ovarian cancer: Patient selection and review of the literature

Bristow

Lagasse

Karlan

1996

Cancer

View full text Add to dashboard Cite

show abstract

Cytoreductive Surgery in Ovarian Carcinoma Patients with a Documented Previously Complete Surgical Response

Cited by 131 publications

References 0 publications

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?

Secondary surgical cytoreduction for advanced epithelial ovarian cancer: Patient selection and review of the literature

Contact Info

Product

Resources

About